Treatment.com AI on front line of the quest to enhance healthcare system efficiency

Treatment.com AI (CSE:TRUE, OTCQB:TREIF) is leveraging its AI platform, including the Global Library of Medicine (GLM), to enhance healthcare efficiency through acquisitions and B2B2C models. Recent acquisitions include Alea Health, an AI-driven mental health platform, and Rocket Doctor, a virtual care platform facilitating over 600,000 patient visits across North America; Rocket Doctor's revenue recognition is expected to begin in Q2, with gross margins near 80% and a path to doubling revenue in the first year, building on its 88% year-on-year increase in 2024. The company aims to integrate its AI to improve patient access, reduce administrative overhead, and enable more profitable healthcare systems, targeting contracts with healthcare organizations and insurers.

Analysis

Treatment.com AI (CSE:TRUE, OTCQB:TREIF) is strategically repositioning itself within the healthcare technology sector by leveraging its proprietary, clinically validated Global Library of Medicine (GLM) AI platform. Under the leadership of CEO Dr. Essam Hamza since late 2023, the company has pivoted from a direct-to-consumer model to a B2B2C approach, targeting hospitals, health systems, and insurers. This strategic shift is supported by key acquisitions, notably Alea Health, an AI-driven mental health platform, and Rocket Doctor, a rapidly expanding virtual and hybrid care platform with over 600,000 patient visits and 300 physicians. Rocket Doctor is particularly significant, as it provides immediate revenue contribution—having grown 88% year-over-year in 2024 with a path to doubling revenue and gross margins near 80%—and serves as a real-world proof of concept for Treatment.com AI's technology. Revenue recognition from Rocket Doctor is expected to commence in the second quarter ending August 31. The company's GLM, developed with over 40,000 hours of clinical expertise, aims to 'think like a doctor' for over 1,000 common diseases, differentiating itself from generic LLMs by minimizing bias. Further validation comes from its selection as one of two Canadian startups in Google’s Inaugural AI First Accelerator. Treatment.com AI is also developing complementary products like a pharmacy triage system and a medical education tool, already in use at the University of Minnesota, as it aims to secure large-scale contracts and scale towards its ambition of becoming a $100 million ARR company.

Key Decisions for Investors

• Investors should evaluate Treatment.com AI's execution of its B2B2C strategy and the integration of recent acquisitions, particularly Rocket Doctor, as key drivers for future growth and market validation.
• Monitor the company's upcoming financial reports, specifically for revenue recognition from Rocket Doctor starting Q2, and its progress towards achieving projected revenue doubling and maintaining high gross margins (near 80%) for this subsidiary.
• Closely track the company's success in securing substantial contracts with healthcare organizations, insurers, and other institutional clients, as this will be critical to scaling its operations and validating its commercial model.
• Consider the competitive landscape and execution risks associated with an emerging company pursuing an aggressive growth and M&A strategy, while acknowledging the positive momentum indicated by recent developments and strong initial metrics from acquisitions.